Physiomics Plc
LLSE:PYC0.48
GBX
0.00
(0.00%)
ISIN
GB00BDR6W943
Return %
Stock
S&P 500
1Y
21.79
14.20
3Y
-69.35
81.12
5Y
-92.28
68.34
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Peter Joseph Sargent
- Full Time Employees
- 11
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Milton Park Innovation Centre Oxfordshire OXF United Kingdom OX14 4RY
- IPO Date
- Dec 20, 2004
- Website
- physiomics.co.uk
- Similar Companies
- Business
- Physiomics Plc is a United Kingdom-based company specializing in providing outsourced quantitative pharmacology, computational biology, mathematical modeling, biostatistics, and data science consultancy services primarily to pharmaceutical and biotechnology companies. Its core offerings include model-informed drug development (MIDD), predictive quantitative systems pharmacology (QSP) through its proprietary Virtual Tumour software, simulation and data analysis services across oncology research and drug development stages, biostatistics, bioinformatics, and technology for personalized medicine. The Virtual Tumour software is a semi-mechanistic model that integrates biological processes such as the cell cycle, DNA damage and repair, and immune response, supporting the design and optimization of preclinical and clinical studies. Founded in 2001 and headquartered in Oxfordshire, England, Physiomics serves clients mainly in the UK, European Union, Switzerland, and the United States. The company leverages industry-standard tools such as NONMEM and MATLAB alongside its proprietary platforms and bespoke R programming models to deliver tailored solutions across drug discovery, preclinical, and clinical phases. It operates within the biotechnology and pharmaceutical sectors, targeting drug developers focused on oncology, personalized medicine, and quantitative pharmacology. Recent major changes include the announcement of the CEO Peter Sargent's planned departure in May 2026 while the non-executive chair, Jim Millen, will resume executive chair responsibilities to ensure business continuity. The company has reported strong business momentum with record contracted projects and revenue growth initiatives, including a new biometrics service line that has already generated revenue. Physiomics also announced the relocation of its registered office to Milton Park Innovation Centre, Oxfordshire, effective October 2025. Furthermore, it secured new contracts in late 2025 to accelerate promising drug programs, demonstrating ongoing commercial progress and strategic growth in model-informed drug development services. Physiomics continues to expand its capabilities through advanced modeling, simulation, AI, and machine learning applications to support its pharmaceutical clients worldwide, maintaining a focus on integrating computational predictions with experimental data to de-risk drug development and improve therapeutic outcomes. The company maintains a lean workforce of approximately 6 to 10 employees and is publicly traded on the London Stock Exchange AIM market under the ticker PYC.L.